These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 2522344)

  • 1. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
    Awwad M; North RJ
    Cancer Res; 1989 Apr; 49(7):1649-54. PubMed ID: 2522344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide-induced tumour regression of cyclophosphamide-resistant L5178Y lymphoma through suppressor cells elimination.
    Andrade-Mena CE
    Int J Tissue React; 1994; 16(2):95-103. PubMed ID: 7960506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
    Berd D; Mastrangelo MJ
    Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
    Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
    Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role of L3T4+ antigen in the Con A response of regenerating splenic L3T4+ T cells after Cy treatment.
    Ikezawa Z; Sato M; Aoki I
    Immunology; 1987 Mar; 60(3):375-82. PubMed ID: 3106196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
    Shu S; Chou T; Rosenberg SA
    Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further observations on the effect of cyclophosphamide on intratumor and peripheral leukocyte levels.
    Evans R
    Am J Pathol; 1980 Jun; 99(3):667-84. PubMed ID: 7386598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen-antibody complexes generate Lyt 1 inducers of suppressor cells.
    Rao VS; Bennett JA; Shen FW; Gershon RK; Mitchell MS
    J Immunol; 1980 Jul; 125(1):63-7. PubMed ID: 6966663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
    Nagarkatti M; Kaplan AM
    J Immunol; 1985 Aug; 135(2):1510-7. PubMed ID: 3159794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
    Evans R; Kamdar SJ; Duffy T; Edison L
    J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Einstein AB; Fass L; Fefer A
    Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclophosphamide on spleen cell suppressor activity and tumour growth in mice.
    Larsen FS; Spärck JV
    Acta Pathol Microbiol Immunol Scand C; 1983 Oct; 91(5):323-33. PubMed ID: 6229132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.